Bristol Myers Squibb has entered into a strategic agreement with Anthropic to deploy Claude Enterprise across its global operations. 

The partnership aims to strengthen the use of artificial intelligence in research, clinical development, manufacturing, commercial activities, and corporate functions.

The company plans to provide Claude’s AI capabilities to more than 30,000 employees. The initiative is designed to move beyond basic chatbot applications and introduce agentic AI systems that can support everyday workflows and decision-making across the organisation.

As part of the agreement, Bristol Myers Squibb will use Claude Code to support engineering and data science teams in accelerating software and AI development. The company expects this approach to improve the integration of data and expertise currently spread across disconnected systems.

The collaboration will also focus on embedding AI agents into key pharmaceutical workflows. In research, AI tools will be used to analyse scientific, molecular, and clinical data to support target identification and optimisation in areas including oncology, haematology, neuroscience, and immunology.

In drug development, the company plans to apply intelligent automation to activities such as preparing clinical study reports, patient safety narratives, and regulatory submissions. The aim is to reduce the time required between clinical data completion and regulatory filing.

Manufacturing and quality operations will also benefit from AI-driven support for root-cause investigations, corrective and preventive action documentation, and batch release decisions. The company expects these improvements to strengthen compliance, speed up decision-making, and support faster medicine delivery.

In commercial and medical affairs, the technology will help organise field insights into structured information to improve engagement with healthcare professionals and deliver more relevant information when needed.

Claude will also be connected to internal systems and repositories containing scientific, clinical, regulatory, and commercial knowledge. Bristol Myers Squibb stated that the deployment will operate with enterprise governance and audit controls.

The agreement builds on more than three years of AI investment by Bristol Myers Squibb. The company has already provided employees with access to multiple frontier AI models through its internal AI platform as part of a broader multi-vendor strategy.

 

Source: businesswire.com

Report Abuse